Through the tissue-specific effects of ER and TR-β treatments, the existence of unique tissue-specific FXR function is a promising avenue to investigate pharmacological strategies that can be implemented in the treatment of NASH. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.